Revelation Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Revelation Biosciences has a total shareholder equity of $6.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $12.2M and $5.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$11.99m |
| Equity | US$6.65m |
| Total liabilities | US$5.56m |
| Total assets | US$12.21m |
Recent financial health updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28Financial Position Analysis
Short Term Liabilities: REVB's short term assets ($12.1M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: REVB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: REVB is debt free.
Reducing Debt: REVB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REVB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: REVB has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 0.8% each year.